Sildenafil |
| رقم الكتالوجGC11369 |
Sildenafil, as a phosphodiesterase-5 (PDE-5) inhibitors, used for treatment of pulmonary arterial hypertension (PAH).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 139755-83-2
Sample solution is provided at 25 µL, 10mM.
Sildenafil, as a phosphodiesterase-5 (PDE-5) inhibitors, used for treatment of pulmonary arterial hypertension (PAH).[1] Sildenafil can also treat erectile dysfunction caused by the psychological stress of infertility treatments.[3]
In vitro, the IC50 of sildenafil for PDE5 was 5.22 nM.[4] In vitro experiment it indicated that treatment with 1 μmol/L sildenafil in pulmonary artery smooth muscle cells potentiated the phosphorylation of ERK1/ERK2, an increase in the percentage of cells in S phase and cell proliferation, compared with serotonin stimulation alone.[5] In vitro, the combination of sildenafil with cisplatin can improve cell toxicity and anticancer effect of cisplatin.[7]
In vivo efficacy test it shown that sildenafil dose-dependently (1 mg/kg every 12 hours for 14 days, p.o.) reduced basal tone and increased electrically-induced relaxation of dog lower oesophageal sphincter samples.[2] In vivo, treatment 10 mg/kg sildenafil after 72 h significantly increased the number of COX-2+ microglia/macrophages in the penumbra, but was remarkably decreased 8 days after ischemia.[6] SILD - EAE mice were treated with 25mg/kg Sildenafil (s.c.), the results shown that sildenafil inhibited nitrosative stress and augmented the levels of LC3, beclin-1, ATG5, p-CREB and BDNF and decreased mTOR levels, as well as augmented p-AMPK.[8] In vivo study it demonstrated that treatment with 40 mg/kg/day sildenafil can improve radiation-induced oral mucositis and decrease the apoptosis of mucosal cells via attenuation of inflammation and oxidative stress.[9]
References:
[1]Bhogal S, et al. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther. 2019 Jul/Aug;26(4):e520-e526.
[2]Quintavalla F, et al. Sildenafil improves clinical signs and radiographic features in dogs with congenital idiopathic megaoesophagus: a randomised controlled trial. Vet Rec. 2017 Apr 22;180(16):404.
[3]Scherzer ND, et al. Sildenafil's impact on male infertility: what has changed in 20 years? Int J Impot Res. 2019 Mar;31(2):71-73.
[4]Wang Z, et al. The selectivity and potency of the new PDE5 inhibitor TPN729MA. J Sex Med. 2013 Nov;10(11):2790-7.
[5]Li BB, et al. Sildenafil potentiates the proliferative effect of porcine pulmonary artery smooth muscle cells induced by serotonin in vitro. Chin Med J (Engl). 2011 Sep;124(17):2733-40.
[6]Moretti R, et al. Sildenafil, a cyclic GMP phosphodiesterase inhibitor, induces microglial modulation after focal ischemia in the neonatal mouse brain. J Neuroinflammation. 2016 Apr 28;13(1):95.
[7]Hassanvand F, et al. Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells. J Cancer Res Ther. 2020 Oct-Dec;16(6):1412-1418.
[8]Duarte-Silva E, et al. Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord. Front Immunol. 2021 May 13;12:671511.
[9]Ala M, et al. Sildenafil improves radiation-induced
| Cell experiment [1]: | |
|
Cell lines |
Bovine aortic endothelial cells |
|
Preparation Method |
Bovine aortic endothelial cells (BAECs), with or without pretreatment of sildenafil (5 μM at 5 minutes before radiation), were used to test endothelial dysfunction in response to external beam radiation at 10e15 Gy. Generation of reactive oxygen species (ROS) was studied. |
|
Reaction Conditions |
5 μM at 5 minutes before radiation |
|
Applications |
sildenafil (5 μM) added 5 minutes before 10 Gy radiation inhibited SDRT-induced apoptosis at 8 hours by 45% from 17.4% (SDRT alone) to 9.6% (SDRTþ sildenafil 5 μM). |
| Animal experiment [2]: | |
|
Animal models |
Male, aged (16-18 months) Wistar rats |
|
Preparation Method |
Male, aged (16-18 months) Wistar rats were subjected to MMI (800 ± 100, 70-100 μm cholesterol crystals injected into the internal carotid artery) and treated with or without Sildenafil (2 mg/kg, i.p) starting at 24 h after MMI daily for 28 days. |
|
Dosage form |
2 mg/kg, i.p |
|
Applications |
Sildenafil treatment in aged MMI rats significantly improves short term memory evaluated by the novel object recognition test and improves spatial learning and memory in the Morris water maze test compared to aged control MMI rats. |
|
References: [1]. Wortel RC, et al. Sildenafil Protects Endothelial Cells From Radiation-Induced Oxidative Stress. J Sex Med. 2019 Nov;16(11):1721-1733. [2]. Venkat P, et al. Sildenafil treatment of vascular dementia in aged rats. Neurochem Int. 2019 Jul;127:103-112. |
|
| Cas No. | 139755-83-2 | SDF | |
| Chemical Name | 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one | ||
| Canonical SMILES | CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C | ||
| Formula | C22H30N6O4S | M.Wt | 474.58 |
| الذوبان | ≥ 46.3 mg/mL in DMSO with ultrasonic, ≥ 22.65 mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1071 mL | 10.5356 mL | 21.0713 mL |
| 5 mM | 0.4214 mL | 2.1071 mL | 4.2143 mL |
| 10 mM | 0.2107 mL | 1.0536 mL | 2.1071 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *